You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 2
  • P01.01 A Phase 1a/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors

Article info

Article menu

Download PDFPDF

E-Poster Presentations
P01 Emerging concepts/novel agents
P01.01 A Phase 1a/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors
Free

Authors

Citation

ABBAS A, Strauss J, Janku F, et al
P01.01 A Phase 1a/1b dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-ITOC7.14

Publication history

  • First published October 1, 2020.
Online issue publication 
October 01, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.